Diabetic Foot Ulcers Pipeline Insights Report, 2019 Edition - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 25, 2019--The “Diabetic Foot Ulcers - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
“Diabetic Foot Ulcers - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Foot Ulcers development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Diabetic Foot Ulcers
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Diabetic Foot Ulcers
The report assesses the active Diabetic Foot Ulcers pipeline products by developmental stage, product type, molecule type, and administration route.
Scope of the reportThe report provides a snapshot of the pipeline development for the Diabetic Foot Ulcers The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Diabetic Foot Ulcers The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Diabetic Foot Ulcers The report also covers the dormant and discontinued pipeline projects related to the Diabetic Foot Ulcers
Companies MentionedANP Technologies Inc Anterogen Co Ltd Boston Therapeutics Inc CardioVascular BioTherapeutics Inc Celgene Corp Chrysalis BioTherapeutics Inc CytoTools AG EyeGene Inc FirstString Research Inc Genentech Inc GlaxoSmithKline Plc Human Stem Cells Institute Izun Pharmaceuticals Corp Lakewood-Amedex Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gn9xkc/diabetic_foot?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190125005430/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL DIABETES
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/25/2019 02:17 PM/DISC: 01/25/2019 02:16 PM